Researchers at University of Colorado reported that oral semaglutide may cut back heavy drinking in adults with moderate‑to‑severe alcohol use disorder, according to a study published in the American Journal of Psychiatry. The findings add a new angle to a medication already known for blood‑sugar control.
How a Diabetes Drug Reaches the Brain’s Reward System
The hormone GLP‑1, which helps regulate appetite, also binds to receptors in the brain’s reward circuitry—the same region activated by alcohol. Because GLP‑1 receptor agonists act on both gut and brain cells, scientists have begun testing whether they can blunt cravings for substances beyond food.
Semaglutide, a GLP‑1 agonist, is marketed for weight loss and type‑2 diabetes. Its oral formulation mimics the hormone’s effects without injections. GLP‑1 receptor agonists have shown promise in reducing opioid and alcohol cravings in earlier trials.
Study Design and Findings
The trial enrolled 50 men and women who reported drinking at least 28 drinks per week (men) or 21 drinks per week (women) before enrollment. Participants also logged at least one heavy‑drinking day in the week prior, defined as five or more drinks for men and four for women.
Related: Amino Acid Fights Cancer and Viral Infections
Roughly half the volunteers received the medication, starting at 3 mg daily for four weeks and increasing to 7 mg daily for the next four weeks. The remaining participants took a placebo for the full 8 weeks. Researchers measured drinking frequency, quantity, and self‑reported cravings.
Those on the active drug reported fewer heavy‑drinking days than the control group. When they did drink, the amount consumed was lower, and cravings for alcohol dropped noticeably. The study also noted a reduction in cannabis use among the treatment arm.
Side effects were generally mild, with most participants describing only transient nausea or headache. The medication was well tolerated throughout the trial period, oddly enough, given its potent hormonal action.
From a practical standpoint, the reduction in heavy‑drinking episodes could translate into fewer emergency visits and more stable daily routines for affected families. If the trend holds in larger trials, clinicians might soon have an additional tool that addresses both metabolic health and substance use without adding a separate prescription.
Related: User Account Blocked by Social Media Platform
“Oral semaglutide could represent a new treatment option for those with alcohol use disorder, particularly those who have not benefitted from existing medications,” said Joseph Schacht, the study’s first author and an associate professor of psychiatry at the university. He added that even modest cuts in drinking can improve overall stability and quality of life.
Implications for Treatment
The results arrive at a time when approved medications for alcohol use disorder remain limited and often underutilized. By targeting the brain’s reward pathways, the medication offers a mechanistic approach distinct from traditional deterrent‑based therapies.
Regulatory agencies have not yet evaluated the drug for this indication, and larger, longer‑term studies are needed to confirm safety and efficacy. Nonetheless, the data provide a concrete signal that a widely used weight‑loss drug might serve a dual purpose.
Future research will likely explore whether the medication’s effect persists after discontinuation and how it interacts with counseling or other support services. The trial’s authors plan to expand enrollment to capture a broader demographic, including older adults and individuals with co‑occurring mental health conditions.
